Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lypsa Gems & Jewellery Limited (LYPSAGEMS.NS)
Mumbai, IN
Lypsa Gems & Jewellery Limited is an Indian firm specializing in the diamond industry. Its comprehensive activities encompass the manufacturing, polishing, and both domestic and international commerce of diamonds, gemstones, and other precious minerals. The company's products reach international markets, including the United States, Belgium, Israel, the United Arab Emirates, and Hong Kong. It primarily serves small and medium-sized diamond manufacturers. Initially established as Maloo Gems & Jewellery Limited, the company officially adopted its current name in August 2011. Founded in 1995, the company maintains its headquarters in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.62% | -1.81% | -4.86% | +3.38% | -3.17% | -11.09% | -43.53% | +13.72% | -14.21% | -91.47% | -93.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Luxury Goods: +16.7%-11.8% Q1'26: -73.1% (vs Q1'25)
-
EPS growth Luxury Goods: +44.9%+111.5% ★ Q1'26: +102.3% (vs Q1'25)
-
FCF margin FCF growth · Luxury Goods: +47.0%-7.8% Q1'26: +53.7% (vs Q1'25)
-
EBIT margin Luxury Goods: +9.4%+3.3% Q1'26: +16.2% (vs Q1'25)
-
ROIC Luxury Goods: +9.9%+1.5% Q1'26: +3.6% (vs Q1'25)
-
Share dilution Luxury Goods: +0.0%-0.4% ★ Q1'26: -2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Luxury Goods: 0.25×20.82× Q1'26: 10.67× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
|---|---|
| Revenue |
2.61B
est: 2.79B (-6.6%)
|
| EBITDA |
256.19M
est: -2.17B (+111.8%)
|
| EBIT |
251.87M
est: -2.19B (+111.5%)
|
| Net Income |
214.97M
est: 212.57M (+1.1%)
|
| SGA |
4.66M
est: 538.28M (-99.1%)
|
| EPS |
7.29
est: 7.21 (+1.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-11 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-10 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-09 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-08 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-05 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-04 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-03 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-02 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-06-01 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-29 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Srishty Mehta | Company Secretary & Compliance Officer | 168.0K | female |
| Dipankumar Babulal Patwa | Chairman & MD | — | male |
| Jeeyan Dipan Patwa | Chief Financial Officer & Executive Director | — | male |
| Manish Jaysukhlal Janani | MD, Chief Executive Officer & Executive Director | — | male |
| Sonal Dipan Patwa | Executive Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LYPSAGEMS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
